4551 — Torii Pharmaceutical Co Balance Sheet
0.000.00%
- ¥122bn
- ¥79bn
- ¥60bn
- 79
- 44
- 93
- 85
Annual balance sheet for Torii Pharmaceutical Co, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | — | JAS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 42,245 | 42,210 | 47,692 | 44,003 | 43,298 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 18,955 | 22,010 | 22,865 | 28,502 | 31,068 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 96,742 | 97,292 | 91,603 | 88,148 | 94,640 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1,777 | 2,078 | 2,282 | 2,095 | 2,451 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 126,026 | 130,810 | 133,689 | 133,432 | 140,664 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 9,461 | 12,372 | 13,221 | 12,504 | 18,153 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 10,935 | 13,795 | 14,465 | 13,298 | 19,131 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 115,091 | 117,015 | 119,224 | 120,134 | 121,533 |
Total Liabilities & Shareholders' Equity | 126,026 | 130,810 | 133,689 | 133,432 | 140,664 |
Total Common Shares Outstanding |